Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis. METHODS: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses. RESULTS: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight. CONCLUSIONS: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.](https://figures.cochat.ai/paper-figures/dfdd355eafec4c6e9c04f1a46b1d736c/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-1.jpg)
![Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.](https://figures.cochat.ai/paper-figures/1a6e539bef254c4eae8e1034fb2ebd96/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These preclinical studies demonstrated a significant reduction in collagen deposition (148).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [148]
In the citing paper
“Pharmacological inhibition of CCL2 by mNOX-E36 (121) or the use of cenicriviroc, a CCR2/CCR5 antagonist, gave promising anti-inflammatory and antifibrogenic results in mouse models (122).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAS, a histological tool developed to assess disease severity in humans, was assessed in a blinded fashion and calculated according to Kleiner’s criteria on H&E-stained sections [38].”
MethodChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Likewise, renal fibrosis is a common manifestation of chronic kidney disease [3], associated with elevated risks of morbidity and mortality [4].”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 2×
“Fibrosis results from a sustained inflammatory response to chronic organ injury and is characterized by the deposition of extracellular matrix proteins, including collagen types 1 and 3 [1].”
BackgroundSelf-citationRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
Background
Research works printed but not linked: 3
- Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
- MM Byron, 2015, Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes, J Immunol, 194, 187, 10.4049/jimmunol.194.Supp.187.8 · DOI
- M Thompson, 2014, Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks, Hepatology, 60, 424A
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Self-citationLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Significant decrease in lobular inflammation, hepatocellular ballooning as well as collagen 1 and α-SMA protein expression in NASH mouse model [334].”
BackgroundTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Kubes, P., & Jenne, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052415 · Cited by 923
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
“The antifibrotic activity of CVC observed here is consistent with findings in several animal models of chronic liver injury.((11)) Although the study did not meet the primary endpoint at year 1, it nonetheless underscores the evolving principles of clinical-trial design that increasingly look to assign endpoints that…”
Self-citationMechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557
“CVC (at a dose of 150mg once daily) is currently being tested in a phase 2b clinical trial in adult patients with NASH and fibrosis (CENTAUR study 652-2-203; NCT02217475) (17).”
BackgroundInfluentialSelf-citationCellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Mieli-Vergani, G., Vergani, D., Czaja, A. J., Manns, M. P., Krawitt, E. L., Vierling, J. M., Lohse, A. W., & Montano-Loza, A. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.17 · Cited by 425
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
“Nowadays, cenicriviroc-related clinical trials have demonstrated that the drug has both antiviral and anti-fibrosis effects in the condition of infections, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) (NCT02653625) and many other conditions.(172,173) In NASH clinical trial (NCT02217475),…”
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., et al. (2020) · Hepatology · doi:10.1002/hep.31108 · Cited by 378
“Another limitation of the study was the limited sample size of patients with severe disease; nonetheless, our post hoc analysis on ≥2-stage fibrosis improvement without impact on underlying steatohepatitis suggests that patients with stage 3 fibrosis may potentially be the ideal target population for CVC. Based on the…”
BackgroundInfluentialXu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
“The apoptosis inducers, such as fraxetin and 4-hydroxy-2(3H)-benzoxazolone have been shown to induce HSC apoptosis in many animal experiments.363,364 Activated HSCs could be killed by the immune surveillance ability of natural killer (NK) cells, suggesting therapeutic activation of NK cells could be an approach to sca…”
BackgroundInfluentialCurrent treatment paradigms and emerging therapies for NAFLD/NASH
Raza, S. (2021) · Frontiers in Bioscience · doi:10.2741/4892 · Cited by 310
“chemokine receptor type 2 (CCR2) and type 5 (CCR5), located on hepatic stellate cells and Kupffer cells is being targeted for anti-fibrosis therapy [165].”
BackgroundLiver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
The ascending pathophysiology of cholestatic liver disease
Jansen, P. L. M., Ghallab, A., Vartak, N., Reif, R., Schaap, F. G., Hampe, J., & Hengstler, J. G. (2017) · Hepatology · doi:10.1002/hep.28965 · Cited by 301
“Reduction of bile viscosity; increasing bicarbonate production UDCA 24-norUDCA Tauro-UDCA TGR5 agonists Urso Falk, Ursochol NorUrso Falk(85) TUDCA(86) INT 777(87) Recommended and approved for PBC PSC, 01755507 PBC, 01829698, 01857284 Not yet in trial 2 3 Increase phospholipid secretion PPARa agonists Fenofibrate(88) B…”
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
“Cenicriviroc Cenicriviroc (CVC) is a dual CCR2/CCR5 chemokine receptor antagonist that has been shown to play key roles in hepatic inflammation and fibrosis.(93,94) In the setting of hepatocyte injury, kupffer cells secrete C-C chemokine ligand type 2 (CCL2) triggering CCR2 receptors to initiate an inflammatory”
The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure
Triantafyllou, E., Woollard, K. J., McPhail, M. J. W., Antoniades, C. G., & Possamai, L. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02948 · Cited by 285
“CVC was previously found to block monocyte recruitment to the liver and exert anti-fibrotic effects in experimental models of liver and kidney fibrosis (130).”
BackgroundMacrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism
Lefere, S., & Tacke, F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.004 · Cited by 278
“Cenicriviroc was able to reduce hepatic monocyte infiltration and fibrosis in mouse steatohepatitis models.(122,144) Results from the CENTAUR phase II trial showed that although cenicriviroc did not lead to resolution of NASH, it doubled the percentage of patients in whom fibrosis was improved by at least 1 stage afte…”
BackgroundTherapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases
van der Heide, D., Weiskirchen, R., & Bansal, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02852 · Cited by 234
Obesity and nonalcoholic fatty liver disease: current perspectives
Sarwar, R., Pierce, N., & Koppe, S. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s146339 · Cited by 232
“Cenicriviroc Cenicriviroc (CVC) is a CCR2/CCR5 chemokine receptor antagonist, which inhibits macrophage recruitment and migration to the liver resulting in reduced inflammation and an antifibrotic effect.(43,44) CVC was evaluated in the CENTAUR study (Efficacy and Safety study of Cenicriviroc for Treatment of NASH in…”
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
Tan, Z., Sun, H., Xue, T., Gan, C., Liu, H., Xie, Y., Yao, Y., & Ye, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730176 · Cited by 215
“Cenicriviroc (CVC) is a dual inhibitor of CCR2 and CCR5, and it reduced the amassment and accumulation of pro-inflammatory macrophages in animal models of liver fibrosis (Lefebvre et al., 2016).”
BackgroundAmbade, A., Lowe, P., Kodys, K., Catalano, D., Gyongyosi, B., Cho, Y., Iracheta‐Vellve, A., Adejumo, A., Saha, B., Calenda, C., et al. (2019) · Hepatology · doi:10.1002/hep.30249 · Cited by 214
Self-citationNonalcoholic Fatty Liver Disease
Wang, X. J., & Malhi, H. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201811060 · Cited by 204
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Makri, E., Goulas, A., & Polyzos, S. A. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.11.010 · Cited by 204
Management Strategies for Liver Fibrosis
Altamirano-Barrera, A., Barranco-Fragoso, B., & Méndez-Sánchez, N. (2017) · Annals of Hepatology · doi:10.5604/16652681.1226814 · Cited by 191
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Argyle, D., & Kitamura, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02629 · Cited by 190
“In mouse models of non-alcoholic steatohepatitis (NASH), treatment with cenicriviroc reduces macrophage recruitment and ameliorates hepatic inflammation as well as fibrosis in the liver (109, 110).”
BackgroundHepatic macrophages: Key players in the development and progression of liver fibrosis
Cheng, D., Chai, J., Wang, H., Fu, L., Peng, S., & Ni, X. (2021) · Liver International · doi:10.1111/liv.14940 · Cited by 188
Therapeutic Landscape for NAFLD in 2020
Neuschwander-Tetri, B. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.051 · Cited by 184
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Guicciardi, M. E., Trussoni, C. E., Krishnan, A., Bronk, S. F., Lorenzo Pisarello, M. J., O'Hara, S. P., Splinter, P. L., Gao, Y., Vig, P., Revzin, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.018 · Cited by 183
Anstee, Q. M., Neuschwander-Tetri, B. A., Wai-Sun Wong, V., Abdelmalek, M. F., Rodriguez-Araujo, G., Landgren, H., Park, G. S., Bedossa, P., Alkhouri, N., Tacke, F., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.003 · Cited by 179
Alisi, A., Carpino, G., Oliveira, F. L., Panera, N., Nobili, V., & Gaudio, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/8162421 · Cited by 167
“The fact that KC recruitment and activation may be driven by chemokine/chemokine receptor system has prompted several experimental studies with pharmacological inhibitors of these pathways [136, 143].”
BackgroundReversal of liver fibrosis: From fiction to reality
Zoubek, M. E., Trautwein, C., & Strnad, P. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.04.005 · Cited by 174
“Cenicriviroc (CVC), an oral antagonist of both, CCR2 and CCR5-dependent pathways, results in a potent inhibition of inflammatory response and fibrogenesis in diverse preclinical models of hepatic fibrosis (63, 146).”
BackgroundFibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
Rockey, D. C., & Friedman, S. L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.065 · Cited by 176
Self-citationMechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 160
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
Polyzos, S. A., Kang, E. S., Boutari, C., Rhee, E.-J., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154203 · Cited by 135
Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
Hu, M., Wang, Y., Liu, Z., Yu, Z., Guan, K., Liu, M., Wang, M., Tan, J., & Huang, L. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00836-6 · Cited by 136
Anstee, Q. M., Neuschwander‐Tetri, B. A., Wong, V. W., Abdelmalek, M. F., Younossi, Z. M., Yuan, J., Pecoraro, M. L., Seyedkazemi, S., Fischer, L., Bédossa, P., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105922 · Cited by 135
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease
She, S., Ren, L., Chen, P., Wang, M., Chen, D., Wang, Y., & Chen, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812431 · Cited by 144
“Conserved cysteine residues are indicated by the red font; N-terminal signal peptide sequence of the mature proteins are indicated by the blue font. le 812431 CCR3, CCR5, and CCR11 (55, 75, 94, 95).”
BackgroundInfluentialThe methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
Li, X., Yuan, B., Lu, M. M., Wang, Y., Ding, N., Liu, C., Gao, M., Yao, Z., Zhang, S., Zhao, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27539-3 · Cited by 129
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
Tacke, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442436 · Cited by 121
“In addition, most animal NASH models also showed either no or mild effects of CVC on hepatocyte ballooning, hepatic inflammation or liver injury markers such as ALT [34, 41], which is in line with the neutral effects of CVC on these parameters in patients.”
BackgroundMethodInfluentialPedrosa, M. C., Seyedkazemi, S., Francque, S., Sanyal, A. J., Rinella, M. E., Charlton, M., Loomba, R. S., Ratziu, V., Kochuparampil, J. G., Fischer, L., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105889 · Cited by 121
Lowe, P., Morel, C., Ambade, A., Iracheta‐Vellve, A., Kwiatkowski, E. R., Satishchandran, A., Fűri, I., Cho, Y., Gyöngyösi, B., Catalano, D., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01972-5 · Cited by 122
Self-citationTissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies
Lemos, D. R., & Duffield, J. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5174 · Cited by 119
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“It has been suggested that the endogenous ligand is a FFA (Kakarala and Jamil, 2014), and/or could be found within serum as serum-starved GPR21-expressing cells display reduced AKT phosphorylation (Leonard et al., 2016).”
BackgroundMartí-Rodrigo, A., Alegre, F., Moragrega, Á. B., Garcia‐García, F., Martí‐Rodrigo, P., Fernández‐Iglesias, A., Gracia‐Sancho, J., Apostolova, N., Esplugues, J. V., & Blas‐García, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318372 · Cited by 118
Sheng, J., Zhang, J., Wang, L., Tano, V., Tang, J., Wang, X., Wu, J., Song, J., Zhao, Y., Rong, J., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324339 · Cited by 111
Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool
Devisscher, L., Scott, C. L., Lefere, S., Raevens, S., Bogaerts, E., Paridaens, A., Verhelst, X., Geerts, A. M., Guilliams, M., & Vlierberghe, H. V. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.006 · Cited by 111
Steatosis in Liver Transplantation: Current Limitations and Future Strategies
Linares, I., Hamar, M., Selzner, N., & Selzner, M. (2018) · Transplantation · doi:10.1097/tp.0000000000002466 · Cited by 113
Regulation and functional roles of chemokines in liver diseases
Cao, S., Liu, M., Sehrawat, T. S., & Shah, V. H. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00444-2 · Cited by 113
Stellate Cells in Tissue Repair, Inflammation, and Cancer
Sherman, M. H. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062855 · Cited by 121
The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application
Zhang, D., Zhang, Y., & Sun, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012572 · Cited by 124
“A THR-b agonist called Resmetirom was evaluated in a Phase III trial, and the latest results showed that it was effective in patients with NAFLD.”
BackgroundInfluentialThe Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
The Role of Myeloid-Derived Cells in the Progression of Liver Disease
Weston, C. J., Zimmermann, H. W., & Adams, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00893 · Cited by 95
Diverse Injury Pathways Induce Alveolar Epithelial Cell CCL2/12, Which Promotes Lung Fibrosis
Yang, J., Agarwal, M., Ling, S., Teitz‐Tennenbaum, S., Zemans, R. L., Osterholzer, J. J., Sisson, T. H., & Kim, K. K. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0297oc · Cited by 96
“interest in dual inhibition of CCR2 and CCR5 as a potential antifibrotic treatment (48).”
BackgroundPydyn, N., Miękus, K., Jura, J., & Kotlinowski, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00020-1 · Cited by 96
Kriegermeier, A. A., & Green, R. R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00149 · Cited by 97
“CVC has previously demonstrated improved inflammatory and fibrosis makers in a rat thioacetamide-induced liver fibrosis model and a diet induced NASH mouse model (154).”
BackgroundMondadori, C., Palombella, S., Salehi, S., Talò, G., Visone, R., Rasponi, M., Redaelli, A. C. L., Sansone, V. C., Moretti, M., & Lopa, S. (2021) · Biofabrication · doi:10.1088/1758-5090/ac0c5e · Cited by 92
“The second compound, CVC, is a double antagonist which blocks both CCR2 and CCR5 and has provided interesting results when used in mouse models of liver and kidney diseases associated with an abnormal macrophage infiltration [52].”
BackgroundNew drugs for NAFLD: lessons from basic models to the clinic
Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 84
“Such anti-inflammatory targets are the aim of clinically investigated anti-NASH agents, the dual CCR2/CCR5 inhibitor cenicriviroc, the VAP-1 (AOC3) inhibitor BI-1467335 (formerly known as PXS-4728A) and the Galectin-3 inhibitor GR-MD-02 [75, 77, 78].”
BackgroundNew Drugs for Hepatic Fibrosis
Shan, L., Wang, F., Zhai, D., Meng, X., Liu, J., & Lv, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874408 · Cited by 95
Lin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 90
Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
Cole, B. K., Feaver, R. E., Wamhoff, B. R., & Dash, A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1410135 · Cited by 85
An update on the recent advances in antifibrotic therapy
Tacke, F., & Weiskirchen, R. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1530110 · Cited by 76
“protein-1, MCP-1) reduced insulin resistance, steatohepatitis, and liver fibrosis in experimental animal models [16,18,64,65].”
BackgroundDrummer, C., Saaoud, F., Jhala, N. C., Cueto, R., Sun, Y., Xu, K., Shao, Y., Lu, Y., Shen, H., Yang, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113883 · Cited by 83
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P., Zeller, A., & Syn, W.-K. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 76
Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance
Roohani, S., & Tacke, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147249 · Cited by 85
Regan, D. P., Coy, J. W., Chahal, K. K., Chow, L., Kurihara, J. N., Guth, A., Kufareva, I., & DOW, S. W. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800619 · Cited by 79
“This model has been previously used for a preclinical evaluation of other small molecule chemokine receptor antagonists (41, 42).”
MethodNovel and emerging therapies for cholestatic liver diseases
Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 77
PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target
She, S., Wu, X., Zheng, D., Pei, X., Ma, J., Sun, Y., Zhou, J., Nong, L., Guo, C., Lv, P., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.033 · Cited by 79
Anstee, Q. M., Lucas, K. J., Francque, S., Abdelmalek, M. F., Sanyal, A. J., Ratziu, V., Gadano, A. C., Rinella, M. E., Charlton, M., Loomba, R. S., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000439 · Cited by 74
“[15,16] 19] In the phase 2b CENTAUR study in patients with NASH, 1-year treatment with CVC resulted in an improvement in fibrosis without worsening of steatohepatitis, reduction of biomarkers of inflammation, and comparable safety and tolerability versus placebo.”
Function of TREM1 and TREM2 in Liver-Related Diseases
Sun, H., Feng, J., & Tang, L. (2020) · Cells · doi:10.3390/cells9122626 · Cited by 76
“Inhibition of CCR2 and CCR5 also suppresses the migration and fibrogenic potential of HSCs [105].”
BackgroundImmunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 79
Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
Connolly, K. A., Belt, B. A., Figueroa, N. M., Murthy, A., Patel, A. P., Kim, M., Lord, E. M., Linehan, D. C., & Gerber, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13287 · Cited by 79
“Tumor-bearing mice were administered 15 mg/ kg of a CCR2/CCR5 antagonist (named CVC, Tobira Therapeutics, CA) [54, 55] or vehicle control (40% Hydroxypropyl-beta-cyclodextrin [Acros Organics] & solutol HS15 [Sigma] in sterile water) subcutaneously (s.”
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
Wattacheril, J. J., Issa, D., & Sanyal, A. J. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052545 · Cited by 72
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Campos-Murguía, A., Ruiz‐Margáin, A., González-Regueiro, J. A., & Macías‐Rodríguez, R. U. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i39.5919 · Cited by 84
Braga, T. T., Corrêa-Costa, M., Silva, R. C., Cruz, M. C., Hiyane, M. I., Silva, J. S., Perez, K. R., Cuccovia, I. M., & Câmara, N. O. S. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0317-4 · Cited by 74
Anti-fibrotic treatments: A review of clinical evidence
Allinovi, M., Chiara, L. D., Angelotti, M. L., Becherucci, F., & Romagnani, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.017 · Cited by 74
Kruger, A. J., Fuchs, B. C., Masia, R., Holmes, J. A., Salloum, S., Sojoodi, M., Ferreira, D. S., Rutledge, S. M., Caravan, P., Alatrakchi, N., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1160 · Cited by 66
“The streptozotocin plus high-fat diet model is limited by a lack of progressive fibrosis, and CVC therapy was only continued for a short-term period (9 weeks) in this dietary model.((12)) Because future NASH therapies in humans, including CVC, may be required for the long term, due to the challenge of adherence to lon…”
BackgroundSelf-citationLiver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Qu, W., Ma, T., Cai, J., Zhang, X., Zhang, P., She, Z., Wan, F., & Li, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.761538 · Cited by 76
“Cenicriviroc is a dual CCR2 and CCR5 antagonist with significant antifibrotic and anti-inflammatory activity in models of fibrosis, such as the mouse peritonitis model, mouse dietinduced NASH model, and rat thioacetamide-induced liver fibrosis model (171).”
BackgroundSendi, H., Mead, I., Wan, M., Mehrab‐Mohseni, M., Koch, K. L., Atala, A., Bonkovsky, H. L., & Bishop, C. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200847 · Cited by 71
Matsuda, M., & Seki, E. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111556 · Cited by 72
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Zhang, C., Zhou, B.-G., Sheng, J., Chen, Y., Cao, Y.-Q., & Chen, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104984 · Cited by 73
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Odagiri, N., Matsubara, T., Sato-Matsubara, M., Fujii, H., Enomoto, M., & Kawada, N. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0187 · Cited by 69
“In fact, a dual CCR2/CCR5 inhibitor, cenicriviroc (CVC) reportedly reduced recruitment of pro-inflammatory macrophages and exerted anti-fibrotic effects in animal models of liver fibrosis.(74,75) Moreover, a phase 2b randomized study (NCT02217475) has reported that after 1 year of CVC treatment, twice as many subjects…”
BackgroundThe role of hepatic macrophages in liver metastasis
Keirsse, J., Damme, H. V., Geeraerts, X., Beschin, A., Raes, G., & Ginderachter, J. A. V. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.010 · Cited by 66
Puengel, T., Krenkel, O., Kohlhepp, M. S., Lefebvre, E. A., Luedde, T., Trautwein, C., & Tacke, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184694 · Cited by 63
Self-citationMotta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 66
“The pathophysiological basis was that the antagonization of these receptors blocks hyperinflammation and fibrogenesis [123].”
BackgroundPuengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126696 · Cited by 59
“Research from our group and others has demonstrated the therapeutic potential of blocking the CCL2/CCR2-mediated monocyte infiltration in the liver [17,41].”
BackgroundMacrophages in Renal Injury, Repair, Fibrosis Following Acute Kidney Injury and Targeted Therapy
Chen, H., Liu, N., & Zhuang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934299 · Cited by 74
“CCL2 mediates fibrosis by stimulating monocyte/macrophage infiltration (96).”
BackgroundFuture Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
Connolly, J. J., Ooka, K., & Lim, J. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00056 · Cited by 66
Dynamic plasticity of macrophage functions in diseased liver
Ritz, T., Krenkel, O., & Tacke, F. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.007 · Cited by 58
Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment
Xiong, P., Zhang, F., Liu, F., Zhao, J., Huang, X., Luo, D., & Guo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114545 · Cited by 59
Parker, R., Weston, C. J., Miao, Z., Corbett, C., Armstrong, M. J., Ertl, L., Ebsworth, K., Walters, M. J., Baumart, T., Newland, D., et al. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00213.2017 · Cited by 56
Metadata
- Authors
- Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., Richards, T., Yoneyama, H., Jenkins, H., Wolfgang, G., & Friedman, S. L.
- Affiliations
- Chelsea and Westminster Hospital (GB)
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- AIDS Research Consortium of Atlanta (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stelic (Japan) (JP)
- Charles River Laboratories (Canada) (CA)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-27
- Volume
- 11
- Issue
- 6
- Pages
- e0158156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4922569
- OpenAlex
- W2467384826
- Cited by
- 323
- References
- 51
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 23 · 2023: 28 · 2022: 33 · 2021: 40 · 2020: 46 · 2019: 30 · 2018: 50 · 2017: 28 · 2016: 8
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute of General Medical Sciences (T32GM007170)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- cenicriviroc, antifibrotic effect, liver fibrosis, renal fibrosis, nonalcoholic steatohepatitis, monocyte/macrophage recruitment, MCP-1, RANTES, hepatic stellate cell activation, collagen deposition, chemokine signaling, thioacetamide-induced liver fibrosis, diet-induced NASH
- MeSH terms
- Animals, Chemotaxis, Fibrosis, Imidazoles, Kidney Diseases, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Sulfoxides, Rats, Sprague-Dawley, Mice, Rats, Receptors, CCR2, CCR5 Receptor Antagonists, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.